HMN 2025: How Inaccuracies are present in key research for blockbuster coronary heart drug ticagrelor

In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has uncovered recent issues, this time in key platelet research utilized in its FDA approval.

For greater than a decade, ticagrelor (Brilinta within the US and Brilique in Europe) has been advisable for sufferers with acute coronary syndrome—a spread of circumstances associated to sudden lowered blood movement to the center.

Last December, an investigation by The BMJ discovered severe knowledge integrity issues within the landmark scientific trial (PLATO) that was used to realize worldwide approval for ticagrelor, calling into query the drug’s benefit over cheaper rivals.

Now, as generic variations of the drug put together to launch this yr, The BMJ has expanded its investigation, taking a look at two key platelet research that AstraZeneca claimed defined ticagrelor’s means to deal with acute coronary syndrome efficiently.

It finds that the “major endpoint” outcomes (the trial’s key measurement) for each scientific trials have been inaccurately reported within the journal Circulation, and divulges that greater than 60 of 282 readings from platelet machines used within the trials weren’t current within the US Food and Drug Administration (FDA) datasets.

What’s extra, one energetic trial investigator by no means grew to become a review writer, whereas one writer advised The BMJ he was not concerned within the trial, and most investigators, together with the principal investigator, have been unreachable or declined to be interviewed.

Victor Serebruany, an adjunct school member at Johns Hopkins University and ticagrelor’s most famous critic, advised The BMJ that “there are episodes of skyrocketing rebound and profound platelet inhibition after ticagrelor, making sufferers vulnerable to thrombosis or bleeding. If docs had recognized what occurred in these trials, they’d by no means have began utilizing ticagrelor.”

Circulation and AstraZeneca didn’t reply to a request for remark.

Serebruany added, “It’s been apparent for years that there’s something unsuitable with the info. That the FDA’s management may look past all these issues—on prime of the various issues their very own reviewers recognized and at the moment are being found by The BMJ—is unconscionable. We all must understand how and why that occurred.”